Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research, Clinical Research, genomics, Diseases, Biological Processes, pathogenesis
METHODS: Here, we isolated malignant plasma cells from bone marrow (BM) samples using CD138+ magnetic-bead or flowcytometry (CD38, CD138, and CD45) sorting from 58 newly diagnosed MM patients. All samples were interrogated by whole-genome sequencing (WGS) to investigate the existence of genomic events acquired before the IGH-translocations and hyperdiploidy. The cohort median coverage was coverage 75x (range 66-94).
RESULTS: To determine whether we could detect potential driver events preceding early and initiating MM drivers, we developed a new chronological analytical model based on the integration of single nucleotide variants (SNV), structural variants (SV) and copy number variants (CNV). This model is composed by two main steps. First, we estimated the molecular time (i.e. corrected ratio between duplicated and non-duplicated clonal SNV) of all large chromosomal duplications and identified the earliest set of chromosomal gains in each patient life. In line with previous evidence (Maura et al. Nat Comm 2019), large trisomies were acquired in the early phases of MM evolution [median molecular time of the earliest gains 0.44 (range 0.10 – 0.75)]. Second, within each early large chromosomal gain we looked for clonal SV mediating CNV loss. A deletion on a large gain can generate three possible scenarios: 1) one of the two duplicated alleles is lost after the gain (i.e. post-gain event) causing a CNV jump from 3:1 to 2:1, where the first number represents the total alleles and the second the minor allele; 2) the deletion occurs on the minor and non-duplicated allele, causing a CNV jump from 3:1 to 2:0. In this scenario it is impossible to time the deletion in relation with the chromosomal duplication; 3) the duplicated allele is involved by a deletion before the duplication (i.e., pre-gain) causing a CNV jump from 3:1 to 1:0. When running this workflow, 5.2% (3/58) of patients in our cohort had large pre-gain deletions mediated by SVs acquired before the earliest multi-chromosomal gain events. All these events involved oncogenes such as ATM, BIRC3, USP8, TCF3. Post-gain loss mediated by SVs were observed in 48.3% (28/58) of patients. Surprisingly, in one patient we observed a pre-gain deletion (3:1 to 1:0) on a large chromosome 11q duplication caused by a t(11;14)(CCND1;IGH). Because the gain occurred simultaneously with the translocation, the deletion must have been acquired before both events. Overall, this is the first evidence that both hyperdiploid and t(11;14)(CCND1;IGH) can be preceded by earlier driver events.
To validate these findings, we performed the same analysis on the MMRF CoMMpass study (n=752 NDMM patients). Despite the low coverage of CoMMpass WGS not allowing for molecular time estimation, we identified pre-gain events and post-gain mediated by SVs in 10.1% (77/752) and 34.6% (260/752), respectively.
CONCLUSION: Due to the development of a new WGS-based chronological model, we revealed the existence of SV acquired before canonical “MM-initiating” events in newly diagnosed MM patients. This data suggests that there may be alternative, previously undescribed, MM-initiating events, which can be explored in a lager dataset using our novel analytical methods.
Disclosures: Diamond: Janssen: Honoraria; Medscape: Honoraria. Dogan: Peer View: Honoraria; Physicians' Education Resource: Consultancy, Honoraria; Incyte: Consultancy; Loxo: Consultancy; Takeda: Other: Research Funding; Roche: Other: Research Funding; EUSA Pharma: Consultancy; Seattle Genetics: Consultancy. Lesokhin: Janssen, Pfizer, Iteos, Sanofi, Genmab: Honoraria; Janssen, Pfizer, BMS, Genentech/Roche: Research Funding; BMS: Honoraria; Amgen: Honoraria; Serametrix, inc: Patents & Royalties; Sanofi: Research Funding; Trillium Therapeutics: Consultancy, Research Funding; Pfizer, Genmab, Sanofi, Iteos, BMS, Janssen: Consultancy; Memorial Sloan Kettering Cancer Center: Current Employment. Davies: Takeda, Abbvie, Amgen, BMS/Celgene, Sanofi, GSK, Janssen: Membership on an entity's Board of Directors or advisory committees. Korde: Amgen, Janssen: Research Funding; Clinical Care Options, OncLive, Intellisphere: Consultancy. Raab: Takeda: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Heidelberg Pharma: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Usmani: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen Pharmaceuticals, Merck, Pharmacyclics, Sanofi, Seagen Inc., formerly Seattle Genetics, Inc., SkylineDX, Takeda: Consultancy; AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen Pharmaceuticals, Oncopeptides, Sanofi, Seagen Inc., formerly Seattle Genetics, Inc., Secura Bio, Inc., SkylineDX, Takeda, TeneoBio , Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen: Research Funding; Amgen, BMS, Janssen Pharmaceuticals, Sanofi: Speakers Bureau. Landgren: Janssen: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials, Research Funding; Pfizer: Consultancy; Merck: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials; Amgen: Research Funding.
See more of: Oral and Poster Abstracts